JP2022160685A5 - - Google Patents

Download PDF

Info

Publication number
JP2022160685A5
JP2022160685A5 JP2022128592A JP2022128592A JP2022160685A5 JP 2022160685 A5 JP2022160685 A5 JP 2022160685A5 JP 2022128592 A JP2022128592 A JP 2022128592A JP 2022128592 A JP2022128592 A JP 2022128592A JP 2022160685 A5 JP2022160685 A5 JP 2022160685A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
dose
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022128592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022160685A (ja
Filing date
Publication date
Priority claimed from JP2019537047A external-priority patent/JP7164530B2/ja
Priority claimed from PCT/US2017/052772 external-priority patent/WO2018057776A1/en
Application filed filed Critical
Publication of JP2022160685A publication Critical patent/JP2022160685A/ja
Publication of JP2022160685A5 publication Critical patent/JP2022160685A5/ja
Priority to JP2024153668A priority Critical patent/JP2024174962A/ja
Pending legal-status Critical Current

Links

JP2022128592A 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 Pending JP2022160685A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024153668A JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201662397988P 2016-09-22 2016-09-22
US62/397,988 2016-09-22
US201762442083P 2017-01-04 2017-01-04
US62/442,083 2017-01-04
US201762443819P 2017-01-09 2017-01-09
US62/443,819 2017-01-09
US201762445774P 2017-01-13 2017-01-13
US62/445,774 2017-01-13
US201762519896P 2017-06-15 2017-06-15
US62/519,896 2017-06-15
EP17306081 2017-08-18
EP17306081.5 2017-08-18
JP2019537047A JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
PCT/US2017/052772 WO2018057776A1 (en) 2016-09-22 2017-09-21 Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019537047A Division JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024153668A Division JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Publications (2)

Publication Number Publication Date
JP2022160685A JP2022160685A (ja) 2022-10-19
JP2022160685A5 true JP2022160685A5 (https=) 2023-01-23

Family

ID=59974890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019537047A Active JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019537047A Active JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Country Status (13)

Country Link
US (1) US20220110999A1 (https=)
EP (2) EP4345110A3 (https=)
JP (3) JP7164530B2 (https=)
KR (3) KR20190053250A (https=)
CN (2) CN118203659A (https=)
AU (2) AU2017332732B2 (https=)
CA (1) CA3037499A1 (https=)
ES (1) ES2974376T3 (https=)
HU (1) HUE066662T2 (https=)
IL (2) IL265516B2 (https=)
MX (3) MX2019003235A (https=)
PL (1) PL3515465T3 (https=)
RU (1) RU2759630C2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2022155404A1 (en) * 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
EP1351704B1 (en) * 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Similar Documents

Publication Publication Date Title
JP2022160685A5 (https=)
JP2025172841A5 (https=)
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
JP2022543815A5 (https=)
JP2019529560A5 (https=)
JP2017507139A5 (https=)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2022543612A5 (https=)
RU2019111921A (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
JP2019531273A5 (https=)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
JP2024102205A5 (https=)
JP2024174962A5 (https=)
JP2020500152A5 (https=)
HRP20181227T1 (hr) Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
JP2023520676A5 (https=)
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
JP2017160178A5 (https=)
JP2018515493A5 (https=)
JP2020502261A5 (https=)
JP2022524204A5 (https=)
JP2015172060A5 (https=)
JP2022523530A5 (https=)
JP2025072440A5 (https=)
JP2024540226A5 (https=)